CYP2C8 and cancer: Previous research has suggested that PXR activation could reduce drug sensitivity and enhance chemoresistance in human cancers through drug‐metabolizing enzymes such as cytochrome P450 2C8 (CYP2C8) as well as ATP‐dependent drug efflux pumps such as P‐glycoprotein (P‐gp) 18.